Precise Insights

Advanced Data and AI for Prostate Cancer

On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.

Prostate Cancer

See some of the 1000s of data elements we offer:

Structured Fields

Request a Demo


Structured Fields


Results from variety of patient tests


Oncology practice visits


Tumor-related observations plus vitals, biometrics, pain, and more


Surgeries, radiation, biopsies, imaging, chemotherapy, etc.


Start and end dates, brand vs. generic codes, dosage, duration, and cycles


Disease state, status, severity, and metastasis

Expert Abstraction

Request a Demo


Expert Abstraction

full ngs panel

Complete genomic report with treatment exposure and clinical outcomes

Disease Progression

Directly-observed measures of critical endpoints

Adverse Events

Different types of adverse responses


Classification into multiple categories

Enriched Data

Request a Demo


Enriched Data

Cost & Utilization

Adjudicated costs with linked claims data

Safety, Comorbidities

Pre-cancer and claims charge events

Specialty Pharmacy & Hub

Rx acquisition status details

Payer & Formulary

Drug tiers and coverage

Social Determinants

Social and physical environment factors

AI & Model-Based Insights

Request a Demo


AI & Model-Based Insights

Cancer Subtype

Cancer type when ICD code is unknown


Predict oft-missing performance score

Metastatic Status

Impute missing data from unstructured notes

Date of Initial Dx

Impute index event

EGFR Status

Impute specific gene mutation

Line of Therapy

Regimen or progression-based drug classes

Patient Adherence

Identify root cause of product switching

Patient Acquisition

Predict factors driving patients’ brand decision

Request Data Count

Explore ConcertAI datasets to see how many patients are in your disease area and meet study criteria.

prostate cancer

Research Studies

Our scientists regularly publish leading RWE studies in the fields of clinical development and health economics and outcomes research.

prostate research study

Treatment Patterns and Effectiveness in mCRPC

Treatments for metastatic castrate-resistant prostate cancer are not well understood. This study examined treatment patterns, sequencing, and outcomes in patients receiving second- and third-line treatment after first-line Docetaxel. 

See Full Study

Retrospective Observational Study

  • Treatment patterns
  • Clinical effectiveness
  • Progression-free survival
  • Overall survival
Patient Features
  • Patients who progressed after line 1 Docetaxel
  • Received line 2 Cabazitaxel (DC), Abiraterone (DA) or other therapy (DO)


Eligible patients

Patients taking Line 2 treatments after Line 1:

Patients receiving DC in line 2 received Abiraterone in Line 3


Patients receiving DC in line 2 received Abiraterone in Line 3

Abiraterone (DA)


Abiraterone (DA)

Increased risk of death in line 2 for DA compared to DC

Patients receiving DC in line 2
received Abiraterone in Line 3


Patients receiving DA in line 2
received Cabazitaxel in Line 3

Patients taking Line 2 treatments after Line 1 Docetaxel:

out of 284 Cabazitaxel (DC)


out of 284
Cabazitaxel (DC)

out of 284 Abiraterone (DA)


out of 284
Abiraterone (DA)

out of 284 Other therapy (DO)


out of 284
Other therapy (DO)


Shorter survival from line 2 for DA compared to DC. Results show that Cabazitaxel may not have been used optimally in the advanced disease setting.

Journal of Community and Supportive Oncology, 2014